These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 1622162)

  • 21. Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species.
    Aldridge KE; Ashcraft D; Cambre K; Pierson CL; Jenkins SG; Rosenblatt JE
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1238-43. PubMed ID: 11257040
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predicting the susceptibility of anaerobes to cefoperazone, cefotaxime, and cefoxitin with the thioglycolate broth disk procedure.
    Zabransky RJ; Birk RJ; Kurzynski TA; Toohey KL
    J Clin Microbiol; 1986 Aug; 24(2):181-5. PubMed ID: 3745418
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of choice of medium on the results of in vitro susceptibility testing of eight antibiotics against the Bacteroides fragilis group.
    Hecht DW; Lederer L
    Clin Infect Dis; 1995 Jun; 20 Suppl 2():S346-9. PubMed ID: 7548594
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Variations in susceptibility to latamoxef(moxalactam) and cefoxitin within the Bacteroides fragilis group.
    Eley A; Greenwood D
    J Antimicrob Chemother; 1984 Mar; 13(3):245-55. PubMed ID: 6725175
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Major methodology-dependent discordant susceptibility results for Bacteroides fragilis group isolates but not other anaerobes.
    Aldridge KE; Schiro DD
    Diagn Microbiol Infect Dis; 1994 Nov; 20(3):135-42. PubMed ID: 7874880
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the E test (PDM epsilometer) and broth microdilution susceptibility tests for members of the Bacteroides fragilis group.
    Murray PR; Niles AC
    Diagn Microbiol Infect Dis; 1991; 14(6):501-5. PubMed ID: 1802537
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differences in the in vitro inhibitory and bactericidal activity of ceftizoxime, cefoxitin, cefotetan, and penicillin G against Bacteroides fragilis group isolates. Comparison of time-kill kinetic studies with MIC values.
    Aldridge KE; Weeks LS; Stratton CW; Sanders CV
    Diagn Microbiol Infect Dis; 1990; 13(4):311-6. PubMed ID: 2076592
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High incidence of cefoxitin and clindamycin resistance among anaerobes in Taiwan.
    Teng LJ; Hsueh PR; Tsai JC; Liaw SJ; Ho SW; Luh KT
    Antimicrob Agents Chemother; 2002 Sep; 46(9):2908-13. PubMed ID: 12183246
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fluoroquinolone resistance in Bacteroides fragilis following sparfloxacin exposure.
    Peterson ML; Hovde LB; Wright DH; Hoang AD; Raddatz JK; Boysen PJ; Rotschafer JC
    Antimicrob Agents Chemother; 1999 Sep; 43(9):2251-5. PubMed ID: 10471574
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An update on the in vitro activity of ceftizoxime and other cephalosporin/cephamycin antimicrobial agents against clinically significant anaerobic bacteria.
    Aldridge KE
    Clin Ther; 1990; 12 Suppl C():3-12. PubMed ID: 2202509
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of microdilution trays (sensititre) for antimicrobial susceptibility testing of Bacteroides fragilis.
    Dornbusch K; Lindmark A; Nord CE
    Med Microbiol Immunol; 1978 Oct; 165(3):147-51. PubMed ID: 723780
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of differences in media and methods on MIC values for anaerobes.
    Wexler HM; Finegold SM
    Hosp Pract (Off Ed); 1990 Oct; 25 Suppl 4():24-30. PubMed ID: 2120269
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Six-year retrospective survey of the resistance of Bacteroides fragilis group species to clindamycin and cefoxitin.
    Wexler HM; Harris B; Carter WT; Finegold SM
    Diagn Microbiol Infect Dis; 1986 Mar; 4(3):247-53. PubMed ID: 3956142
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of kill-kinetic studies with agar and broth microdilution methods for determination of antimicrobial activity of selected agents against members of the Bacteroides fragilis group.
    Stratton CW; Weeks LS; Aldridge KE
    J Clin Microbiol; 1987 Apr; 25(4):645-9. PubMed ID: 3571474
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the bactericidal activity of clindamycin and metronidazole against cefoxitin-susceptible and cefoxitin-resistant isolates of the Bacteroides fragilis group.
    Stratton CW; Weeks LS; Aldridge KE
    Diagn Microbiol Infect Dis; 1991; 14(5):377-82. PubMed ID: 1797454
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Factors affecting the in vitro activity of cefoperazone against the Bacteroides fragilis group.
    Sutter VL; Kwok YY
    Antimicrob Agents Chemother; 1981 Dec; 20(6):723-5. PubMed ID: 6459765
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Beta-lactamase production, beta-lactam sensitivity and resistance to synergy with clavulanate of 737 Bacteroides fragilis group organisms from thirty-three US centres.
    Jacobs MR; Spangler SK; Appelbaum PC
    J Antimicrob Chemother; 1990 Sep; 26(3):361-70. PubMed ID: 2228827
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasmid-related resistance to cefoxitin in species of the Bacteroides fragilis group isolated from intestinal tracts of calves.
    dos Santos Almeida F; Avila-Campos MJ
    Curr Microbiol; 2006 Nov; 53(5):440-3. PubMed ID: 17019644
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibiotic susceptibility profiles of Bacteroides fragilis and Bacteroides thetaiotaomicron in Japan from 1990 to 1992.
    Tanaka-Bandoh K; Kato N; Watanabe K; Ueno K
    Clin Infect Dis; 1995 Jun; 20 Suppl 2():S352-5. PubMed ID: 7548596
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Resistance trends of Bacteroides fragilis group over an 8-year period, 1997-2004, in Korea.
    Roh KH; Kim S; Kim CK; Yum JH; Kim MS; Yong D; Lee K; Kim JM; Chong Y
    Korean J Lab Med; 2009 Aug; 29(4):293-8. PubMed ID: 19726890
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.